1 Apr 2020 16:00
1 April 2020
RTW Venture Fund Limited
(the "Company")
Change of Name of Administrator/Company Secretary
The Company announces that, following the announcement of the merger of the Ocorian and Estera groups on 10 February 2020, the Company's Administrator and Company Secretary, Estera International Fund Managers (Guernsey) Limited has legally amalgamated with its affiliate company Estera Administration (Guernsey) Limited. The amalgamated company will continue to act in its capacity as administrator and company secretary but will change its name to Ocorian Administration (Guernsey) Limited on 6 April 2020.
For further information, please contact:
RTW Investments, LP +1 (646) 343 9280 Stephanie Sirota, Chief Business OfficerAlexandra Taracanova, PhD, Director of Investor Relations Julia Enright, Business Development Associate
Ocorian +44 (0) 1481 742 642 Kevin Smith
|
J.P. Morgan Cazenove +44 (0)20 7742 4000 William Simmonds Oliver Kenyon James Bouverat (Sales)
Barclays +44 (0)20 7623 2323 Tom Swerling Andrew Tusa Ryan McCarthy
|
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.
Rtw Biotech (RTW)